More About Us

Quay Pharma are unique in both the academic standing of our scientists, and our drive to discover the most elegant and effective response, not the first or most obvious, to every challenge of drug delivery and dosage. Our senior commercial and technical team brings together an impressive breadth and depth of experience from academia, the pharmaceutical industry and contract service organisations. Their expertise covers chemistry, analytical chemistry, preclinical and clinical formulation development, pharmaceutical development and quality assurance.

Professor Mike Rubinstein

Professor Mike Rubinstein
Chairman & Founder

Mike is the Chairman and founder of Quay Pharma. A chemical engineer and pharmacist with Qualified Person (QP) status, he has over 30 years of experience in solid dosage form design, development and manufacture. Before founding Quay Pharma, he was Professor of Pharmaceutical Technology and Director of the School of Pharmacy and Chemistry at Liverpool John Moores University. He is the author of five books on pharmaceutical technology, owns two patents and has published more than 200 research papers and articles. His experience includes work with AstraZeneca and GlaxoSmithKline in both R&D and production.

Maireadh Pedersen

Maireadh Pedersen
Chief Executive Officer

Maireadh is the Chief Executive Officer of Quay. She brings more than 16 years experience of business development in an international marketing environment, dealing with the supply of analytical tools and equipment as well as formulation technologies for the pharmaceutical industries. Maireadh’s previous roles include two years as VP with responsibility for Pharmaceutical Business Development at Teraview and eight years at Colorcon managing their EMEA film coating and excipients business.

Mike Frodsham

Mike Frodsham
Chief Technical Officer (CTO)

Mike has over 20 years’ experience in drug product development. For over 15 years he has been responsible for development activities at Quay Pharma. During this period Mike has overseen over 200 non-sterile development projects; predominantly taking NCE’s through to first in man studies and beyond. His background is in formulation science with a PhD in liquisolid dosage forms and is cited as an inventor on multiple oral formulation patents.

 Professor John Collett

Professor John Collett
Chief Scientific Officer

John is Quay Pharma’s Chief Scientific Officer and Professor of Pharmaceutics at the University of Manchester. He has over 30 years of experience in formulation science and is the author of more than 250 research papers. His areas of expertise include the formulation of solubilised and modified release drug delivery systems.

Professor Larry Gifford

Professor Larry Gifford
Chief Scientific Officer

Professor Larry Gifford has been appointed as a Chief Scientific Officer. Alongside Professor John Collett. Prof. Gifford joins us from Keele University where he was Deputy Head of the School of Pharmacy. Prior to Keele, Prof. Gifford taught at the University of Manchester and during his final seven years at Manchester was Head of School, whilst leading an EPSRC post-graduate M.Sc. in Pharmaceutical analysis.and his main interests lie in solid dosage form technology and tablet compression.

Joe Young

Joe Young
Trainee QP & Quality Manager

Joe is a Trainee QP & Quality Manager who has over 22 years’ experience in Quality focussed roles. Joe is currently responsible for certification of unlicensed finished products and supporting the Head of Quality/QP to certify licenced Finished product and IMPs. Previously Joe was responsible for Quality control at Quay for 11 years where he oversaw QC release of raw materials, finished products, stability testing, and equipment cleaning verification. Prior to Quay, he worked in Quality Control as Senior Analyst for 7 years at GlaxoSmithKline.

Melanie Ackerley

Melanie Ackerley
Head of Quality

Melanie Ackerley is Quay Pharma’s Head of Quality and has been a releasing QP since 2016. Melanie has a degree in Microbiology and Diploma in Quality Assurance and has worked for 20 years in QA, QC and Validation roles in Pharma covering biologics, steriles, blow fill seal and solid dose. Melanie has held previous roles as Head of Quality, Head of QC and Site Microbiologist at a mix of large Pharma companies, as a consultant and in contract manufacturing.

Michael Kruidenier

Michael Kruidenier
Head of Business Development

Michael joined Quay Pharma in Sept 2013 and he is responsible for all global Live Biotherapeutic business and for all other business outside Europe. Most of Michael’s career has been spent in commercial roles. He has over 30 years of Sales and Marketing experience, including 20 years in the pharmaceutical industry with Proctor & Gamble and SCA followed by working for leading contract service organisations PERA and Penn Pharma.

Audrey Vardy

Audrey Vardy
Head of Business Development - Pre-Clinical

Audrey is the Head of Business Development for Quay’s Pre-Clinical Services. She has 15 years’ experience within the pre-clinical contract research world holding both Operational and Commercial positions during that time. Spending 6 years at CXR Biosciences, Audrey was laboratory team leader, before joining the sales team as BDM, then Sales Manager. She then joined BD Biosciences as their European Key Account Manager being responsible for both contract services and drug metabolism research products. Before joining Quay Pharma in 2018, Audrey returned to CXR (then Concept Life Sciences) for 4 years as Principal Scientist and Head of Operations. Audrey also has a Ph.D. in Neurosciences.

Alison Foster

Alison Foster
Head of Technical - Pre-Clinical

Alison is the Head of Technical for Pre-Clinical Services at Quay. She has a wide breadth of experience having worked previously for Unilever in their cross-category research unit focused on Oral Care and Hair projects, to being one of the founders of a small nanotechnology start-up company focussed on improving bioavailable of poorly soluble drugs. Alison gained Post-Doctoral experience in medicinal chemistry from the School of Pharmacy, University of Manchester following a Ph.D. in synthetic chemistry. She is co-author of 25 patents and 9 papers.

David Blum

David Blum
Managing Director (Israel)

David joined Quay as Managing Director of the company's Israeli subsidiary to expand its presence providing CDMO services in Israel with particular emphasis on oral dosage forms, cannabis and live-biotherapeutics. He holds a degree in Pharmacy from the Hebrew University of Jerusalem and an MBA from the University of Leicester and is certified by the Israeli Ministry of Health as Appointed Pharmacist, QP & QPPV. He has about 30 years of experience working with at least a dozen companies dealing in pharmaceuticals, drug discovery and medical device development and has held positions of influence spanning business development, plant management, supply chain management, manufacturing, CMC development, quality assurance, regulation and pharmacovigilance.

Maura McArdle

Maura McArdle
Head of Business Development for Europe

Maura McArdle joined Quay as Head of Business Development for Europe in 2019. Maura’s appointment is to ensure continued focus on Quay’s core business, Pharmaceutical Development of small molecule compounds. With a degree in Chemical Engineering, Maura has over 20 years business development experience into the Chemical and Pharmaceutical industries having previously worked for Almac, Brenntag and BASF.

For all sales enquiries, call us on +44 (0)1244 837000 and a member of our Business Development team will be happy to help. Alternatively, fill out a quick form on our contact page.

Contact Us